This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05618028
Recruitment Status : Recruiting
First Posted : November 16, 2022
Last Update Posted : February 5, 2024
Information provided by (Responsible Party):

Brief Summary:

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy.

ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult participants will be enrolled in the study across sites worldwide.

In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. In part 3 (dose expansion), participants will receive the RP2D oral dose of ABBV-525. The estimated duration of the study is up to 64 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Condition or disease Intervention/treatment Phase
Diffuse Large B-Cell Lymphoma Chronic Lymphocytic Leukemia B Cell Malignancies Non-Hodgkin's Lymphoma Drug: ABBV-525 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies
Actual Study Start Date : April 4, 2023
Estimated Primary Completion Date : June 27, 2027
Estimated Study Completion Date : June 27, 2027

Arm Intervention/treatment
Experimental: ABBV-525 Dose Escalation
Participants will receive escalating doses of ABBV-525 until doses for optimization are determined, as part of an approximately 64 month study period.
Drug: ABBV-525
Oral; Tablet

Experimental: ABBV-525 Dose Optimization
Participants will receive one of two doses of ABBV-525 until the recommended phase 2 dose (RP2D) is determined, as part of an approximately 64 month study period.
Drug: ABBV-525
Oral; Tablet

Experimental: ABBV-525 Dose Expansion
Participants will receive the RP2D dose of ABBV-525, as part of an approximately 64 month study period.
Drug: ABBV-525
Oral; Tablet

Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AE) [ Time Frame: Up to Approximately 64 Months ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence, whether associated with study drug or not, that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event requiring medical or surgical intervention to prevent serious outcome.

  2. Number of Participants With Dose-Limiting Toxicities (DLT) [ Time Frame: Up to Approximately 28 Days ]
    A DLT is defined as any AE for which a clear alternative cause cannot be established (eg, attributed to the disease under study, another disease, or to a concomitant medication by the study investigators or medical monitor).

  3. Number of Tumor Lysis Syndrome (TLS) [ Time Frame: Up to Approximately 64 Months ]
    TLS is confirmed by evaluation of electrolyte and fluid status and renal status including urine output.

  4. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters [ Time Frame: Up to Approximately 64 Months ]
    Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator will assess the results for clinical significance.

  5. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters [ Time Frame: Up to Approximately 64 Months ]
    Vital sign parameters included body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance.

  6. Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG) [ Time Frame: Up to Approximately 64 Months ]
    A standard 12-lead ECG will be performed. The investigator will assess the results for clinical significance.

  7. Maximum Observed Plasma Concentration (Cmax) of ABBV-525 [ Time Frame: Up to 12 Months ]
    Maximum observed plasma concentration of ABBV-525.

  8. Time to Cmax (Tmax) of ABBV-525 [ Time Frame: Up to 12 Months ]
    Time to Cmax of ABBV-525.

  9. Area Under the Plasma Concentration-Time Curve (AUC) of ABBV-525 [ Time Frame: Up to 12 Months ]
    Area under the plasma concentration-time curve of ABBV-525.

Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: Up to Approximately 64 Months ]
    ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR)/very good partial response (VGPR)/partial response (PR) in participants receiving at least 1 dose of study drug.

  2. Duration of Response (DOR) [ Time Frame: Up to Approximately 64 Months ]
    DOR is defined for participants achieving CR/VGPR/PR as the time from the initial response per Investigator review to disease progression or death of any cause, whichever occurs earlier.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dose Escalation (Part 1) Only: Participants with a documented diagnosis of one of the following third line or later of treatment (3L)+ mature B-cell malignancies, from the World Health Organization (WHO)-defined histologies as defined in the protocol.
  • Dose Optimization (Part 2) Only: Participants with documented diagnosis of chronic lymphocytic leukemia (CLL) who are 3L+, +/- cysteine-to-serine point mutation at residue 481 of BTK-domain active site (C481S with histology based on WHO criteria, with measurable disease requiring treatment as defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
  • Dose Expansion (Part 3) Only: Participants with documented diagnosis of non-germinal center B cell (GCB) Diffuse large B-cell lymphoma (DLBCL) who are 3L+ chimeric antigen receptor T-cells (CAR-T)/Hematopoietic cell transplant (HCT) relapsed/refractory (R/R) and/or ineligible with histology based on WHO criteria, with measurable disease requiring treatment.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
  • Participant has a life expectancy >= 12 weeks.
  • Adequate hematological and hepatic function as defined in the protocol.
  • Must have archival or freshly collected tumor tissue for correlative studies before study enrollment.
  • Participants with prior central nervous system (CNS) disease that has been effectively treated may be eligible.
  • Participants with resolved coronavirus disease 2019 (COVID-19) infection are eligible.

Exclusion Criteria:

  • Known active CNS disease, or primary CNS lymphoma.
  • Known bleeding disorders.
  • Known history of stroke or intracranial hemorrhage within 12 months prior to first dose of study treatment.
  • Uncontrolled active systemic infection, or active cytomegalovirus infection.
  • Active hepatitis B or C infection.
  • Known history of human immunodeficiency virus (HIV).
  • Known active COVID-19 infection. Participant must not have signs/symptoms associated with COVID-19 infection or known exposure to a confirmed case of COVID-19 infection during screening. If participant has signs/symptoms suggestive of COVID-19 infection, the participant must have a negative molecular (eg, polymerase chain reaction) test or 3 negative antigen test results at least 24 hours apart.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05618028

Layout table for location contacts
Contact: ABBVIE CALL CENTER 844-663-3742

Layout table for location information
United States, Florida
Mount Sinai Medical Center-Miami Beach /ID# 248251 Recruiting
Miami Beach, Florida, United States, 33140-2948
United States, Indiana
Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113 Recruiting
Fort Wayne, Indiana, United States, 46804
United States, Louisiana
Tulane Cancer Center Clinic /ID# 249586 Recruiting
New Orleans, Louisiana, United States, 70112
United States, Michigan
Cancer & Hematology Centers /ID# 252359 Recruiting
Grand Rapids, Michigan, United States, 49503
United States, New York
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 245459 Recruiting
New York, New York, United States, 10065-6007
United States, North Carolina
Levine Cancer Ins, Carolina Me /ID# 246363 Recruiting
Charlotte, North Carolina, United States, 28204
United States, Texas
University of Texas MD Anderson Cancer Center /ID# 245463 Recruiting
Houston, Texas, United States, 77030
Australia, Victoria
Monash University /ID# 246366 Recruiting
Clayton, Victoria, Australia, 3168
Alfred Health /ID# 248592 Recruiting
Melbourne, Victoria, Australia, 3004
Rabin Medical Center /ID# 257665 Recruiting
Haifa, H_efa, Israel, 4941492
Shamir Medical Center (Assaf Harofeh) /ID# 257711 Recruiting
Be'er Yaakov, HaMerkaz, Israel, 70300
The Chaim Sheba Medical Center /ID# 251442 Recruiting
Ramat Gan, Tel-Aviv, Israel, 5265601
Hadassah Medical Center-Hebrew University /ID# 251441 Recruiting
Jerusalem, Yerushalayim, Israel, 91120
Sponsors and Collaborators
Layout table for investigator information
Study Director: ABBVIE INC. AbbVie
Layout table for additonal information
Responsible Party: AbbVie Identifier: NCT05618028    
Other Study ID Numbers: M23-324
First Posted: November 16, 2022    Key Record Dates
Last Update Posted: February 5, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Diffuse Large B-Cell Lymphoma
B-cell Malignancies
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Chronic Disease
Disease Attributes
Pathologic Processes